# Phase 6 Critique — GHK-Cu

## Verdict

verdict: PASS (no CRITICAL gaps)

Adversarial read of the synthesized GHK-Cu report against the four mandated axes. I did not write this draft. The report is unusually disciplined: the topical-vs-injectable firewall, the Pickart commercial-COI carry-forward, the negative/null counter-evidence weighting, the cMap/anti-cancer prediction framing, and the WADA S0/S2 hedging are all handled correctly and consistently. No CRITICAL gap exists; findings below are minor/major and do not force HALT. No additional retrievals were required — the corpus was verified at @99 in-pipeline and no specific counter-claim genuinely needed re-testing.

## Findings

Axis-by-axis adversarial result, then enumerated findings.

**Axis 1 (missing perspectives / counter-evidence / bias) — PASS.**
- *Topical-vs-injectable distinction:* applied consistently, not just in the intro. The "no human study of any design exists for injectable/systemic GHK-Cu" statement is repeated in ≥7 distinct locations: intro blockquote (§ lead-in), risk_tier metadata, §3 header, §3.5, §3.6, §6 (tier justification), §8.2/§8.4, §10, §11, and the one-sentence bottom line. This is the report's strongest discipline.
- *Pickart commercial-COI carry-forward:* present at intro, §2 caveat, §2.3, §2.6, §5 (elevated to first-class concern), §7.5, §7.6, §11, and per-entry in the bibliography. The "denied-COI" gap (BioMed Res Int 2015 declaring no COI despite all-author Skin Biology affiliation) is surfaced twice. Carried into every review-leaning claim — correct.
- *Miller 2006 negative + Parker 2013 null:* both given fair (arguably generous) weight — Miller at the table, §3.3, §6, §10, §11; Parker at §6, §7.3, bibliography. Both appear in the tier-C "what holds it down" list.

**Axis 2 (logical consistency / citation completeness / balance / tone) — PASS with minor findings.** Two orphaned bibliography entries; otherwise internally consistent, non-promotional, goal-agnostic.

**Axis 3 (overstatement check) — PASS.** cMap "31.2% / gene-resetting" framed throughout as a bioinformatic prediction from 3 microarray profiles (2 PC3 + 1 MCF7), single 1 µM dose, no replication; anti-cancer explicitly "NOT a demonstration … no GHK treatment performed"; endogenous 200→80 ng/mL decline flagged as 1973 UCSF thesis, uncited-in-review, single-source grey-lit; copper-overload/Wilson's correctly scoped to systemic/injectable use with the UL (10 mg/day, liver endpoint) and absolute-contraindication framing.

**Axis 4 (regulatory / WADA accuracy) — PASS.** CIR 2018 "safe as used" correctly scoped to topical only; injectable unapproved + 503A flux (Category-1 removal, PCAC pending Feb 2027) accurate and flagged time-sensitive; WADA not-individually-named + S0 catch-all + unsettled-S2 "similar biological effect" argument correctly presented as an argument an authority *could* make, not a settled ban.

Enumerated findings:

1. **citation-incomplete / minor** — Refs [50] (Avena Lab 5000 ppm TDS) and [62] (Fu SC et al. 2015, ACL/orthopaedic animal GHK-Cu study, PMID 25731775) appear in the bibliography but are never cited by an inline `[N]` token in the body. Orphaned references; no claim is wrong, but they should either be wired into the text or dropped.

2. **unexamined-counter-evidence / minor** — Ref [62] (Fu 2015) is an *independent animal* GHK-Cu study whose own result is "**transiently** improved healing outcome." That null-leaning nuance is a relevant third data point for the §7.3 model-dependence discussion (alongside the Parker 2013 irradiated-flap null), but it is left as an orphan rather than folded into the wound-signal balance. Omission is in the conservative direction (it would *strengthen*, not weaken, the "model-dependent" caveat), so non-blocking — but it is genuine counter-evidence left on the table.

3. **balance-issue / minor** — The tier-C "pull up" leans materially on Mulder 1994 as "the highest-quality controlled human design / one positive RCT." The report does disclose every caveat (n unstated, ProCyte/industry COI, 30 years old, wound-healing not cosmetic), but the §6 and §11 framing still reads as "one positive RCT," which sounds more robust than an n-unstated, single, industry-sponsored, three-decade-old trial actually is. A one-clause reminder at the §6/§11 summary level that this single pillar is itself thin (not just elsewhere in §3.3) would tighten the balance. Disclosed, not hidden — minor.

4. **objectivity-issue / minor** — The "31.2%" cMap figure, though always correctly framed as a prediction, is repeated as a numeric headline in §2.3, §7.5, and §7.6. Each instance is hedged, but repeating the specific number this many times gives a precise-sounding figure more salience than its 3-profile basis warrants. Tone is non-promotional overall; this is a salience nit, not a misstatement.

None of the four rise to CRITICAL. The report's honest-evidence-state discipline is intact across all mandated axes.

## Structured verdict

```json
{"phase":"6","critique_agent_id":"critique-ghkcu-i1","draft_path":"vault/library/peptides/ghk-cu/research-report.md","findings":[{"category":"citation-incomplete","severity":"minor","description":"Refs [50] (Avena Lab TDS) and [62] (Fu 2015 ACL/orthopaedic animal study, PMID 25731775) are in the bibliography but never cited by an inline [N] token in the body — orphaned references; wire in or drop."},{"category":"unexamined-counter-evidence","severity":"minor","description":"Ref [62] Fu 2015 is an independent animal GHK-Cu study reporting only TRANSIENTLY improved healing; this null-leaning nuance belongs in the §7.3 model-dependence/wound-signal balance alongside Parker 2013 but is left orphaned. Omission is conservative (would strengthen the model-dependent caveat), hence non-blocking."},{"category":"balance-issue","severity":"minor","description":"The tier-C 'pull up' and §6/§11 summaries lean on Mulder 1994 as 'one positive RCT / highest-quality human design.' All caveats (n unstated, ProCyte COI, 30 years old, wound-not-cosmetic) are disclosed in §3.3, but the summary-level 'one positive RCT' framing still reads more robust than an n-unstated single industry trial warrants; a one-clause thinness reminder at §6/§11 would tighten balance."},{"category":"objectivity-issue","severity":"minor","description":"The cMap '31.2%' figure, always correctly framed as a bioinformatic prediction, is repeated as a precise numeric headline in §2.3, §7.5, and §7.6, giving a 3-profile-based number more salience than its basis warrants. Salience nit, not a misstatement; tone is non-promotional overall."}],"additional_retrievals":[],"halt_reasons":[],"iterations":1}
```
